2002
DOI: 10.1016/s0010-7824(01)00316-x
|View full text |Cite
|
Sign up to set email alerts
|

An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
21
0
1

Year Published

2005
2005
2018
2018

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 53 publications
(27 citation statements)
references
References 20 publications
5
21
0
1
Order By: Relevance
“…These results suggest that the use of DRP can reduce the metabolic concerns that are specific to women with PCOS, regarding the possible use of OCs in these women. Oral contraceptives containing 30 mg or more of EE associated with second-generation progestins, such as levonorgestrel, decrease peripheral insulin receptors (25) and induce subclinical abnormalities in carbohydrate metabolism (26,27). Oral contraceptives with third-generation progestins (desogestrel and gestodene, norgestimate) are considered more neutral (28)(29)(30), but in some studies a decrease in insulin sensitivity has been reported (31)(32)(33).…”
Section: Discussionmentioning
confidence: 99%
“…These results suggest that the use of DRP can reduce the metabolic concerns that are specific to women with PCOS, regarding the possible use of OCs in these women. Oral contraceptives containing 30 mg or more of EE associated with second-generation progestins, such as levonorgestrel, decrease peripheral insulin receptors (25) and induce subclinical abnormalities in carbohydrate metabolism (26,27). Oral contraceptives with third-generation progestins (desogestrel and gestodene, norgestimate) are considered more neutral (28)(29)(30), but in some studies a decrease in insulin sensitivity has been reported (31)(32)(33).…”
Section: Discussionmentioning
confidence: 99%
“…The thromboembolic risks of the newer formulations of COCs and nonoral formulations are not known. COCs have been shown to have a negative impact on the lipid profi le (reduction in high-density lipoproteins and increase in low-density lipoproteins/triglycerides) [12] and glucose metabolism [13]. Use of COCs is associated with an increase in blood pressure [14,15].…”
Section: Combined Hormonal Contraceptivesmentioning
confidence: 99%
“…Studies in pre-menopausal women using OCs have shown a dose related response in the lipid profile. Women using a 20-µg EE/100-µg LNG OC demonstrated reductions in high density lipoprotein cholesterol (HDL-C) and small increases in LDL-C and triglycerides, in contrast to a 30-µg EE/150-µg LNG OC 22 . The amount of lipid alteration also depends on the delivery route, where transdermal contraceptive hormone delivery is relatively less potent compared with oral.…”
Section: Resultsmentioning
confidence: 99%